Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients
Transplant International · 2024
DOI: 10.3389/ti.2024.12712 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant International, 2024. Verfasst von Nathalie Hammer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service of Nephrology and Hypertension, Inselspital, Bern, Switzerland. Hauptthemen laut MEDLINE: Valganciclovir, Kidney Transplantation, Cytomegalovirus Infections, Antiviral Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Valganciclovir (VGC) is administered as prophylaxis to kidney transplant recipients (KTR) CMV donor (D)+/recipient (R)− and CMV R+ after thymoglobulin-induction (R+/TG). Although VGC dose adjustments based on renal function are recommended, there is paucity of real-life data on VGC dosing and associations with clinical outcomes. This is a retrospective Swiss Transplant Cohort Study-embedded observational study, including all adult D+/R− and R+/TG KTR between 2010 and 2020, who received prophylaxis with VGC. The primary objective was to describe the proportion of inappropriately (under- or over-) dosed VGC week-entries. Secondary objectives included breakthrough clinically significant CMV infection (csCMVi) and potential associations between breakthrough-csCMVi and cytopenias with VGC dosing. Among 178 KTR, 131 (73.6%) patients had ≥2 week-entries for the longitudinal data of interest and were included in the outcome analysis, with 1,032 VGC dose week-entries. Overall, 460/1,032 (44.6%) were appropriately dosed, while 234/1,032 (22.7%) and 338/1,032 (32.8%) were under- and over-dosed, respectively. Nineteen (14.5%) patients had a breakthrough-csCMVi, without any associations identified with VCG dosing ( p = 0.44). Unlike other cytopenias, a significant association between VGC overdosing and lymphopenia (OR 5.27, 95% CI 1.71–16.22, p = 0.004) was shown. VGC prophylaxis in KTR is frequently inappropriately dosed, albeit without meaningful clinical associations, neither in terms of efficacy nor safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service of Nephrology and Hypertension, Inselspital, Bern, Switzerland.
- Swiss Transplant Cohort Study (STCS), University Hospital Basel, Basel, Switzerland.
- Service of Nephrology, Geneva University Hospitals (HUG), Geneva, Switzerland.
- Service of Infectious Diseases, Inselspital, Bern, Switzerland.
- Transplant Infectious Diseases Unit, Service of Infectious Diseases, HUG, Geneva, Switzerland.
Zitieren
APA
Hammer, N., Hoessly, L., Haidar, F., Hirzel, C., de Seigneux, S., van Delden, C., Vogt, B., Sidler, D., & Neofytos, D. (2024). Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients. Transplant International. https://doi.org/10.3389/ti.2024.12712
Vancouver
Hammer N, Hoessly L, Haidar F, Hirzel C, de Seigneux S, van Delden C, et al. Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients. Transplant International. 2024. doi:10.3389/ti.2024.12712
BibTeX
@article{Hammer2024,
author = {Hammer, Nathalie and Hoessly, Linard and Haidar, Fadi and Hirzel, Cédric and de Seigneux, Sophie and van Delden, Christian and Vogt, Bruno and Sidler, Daniel and Neofytos, Dionysios},
title = {Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.12712}
}
EUVIMED